Merck's earnings call highlights strong progress in clinical trials, particularly for luspatercept in hematological cancers.  Positive Phase 3 data and anticipated FDA submissions in the first half of 2019 indicate potential for positive stock movement.  Trials in neuromuscular and pulmonary diseases show promising preliminary results, further supporting near-term growth potential.
[1]
